Heading Towards a Potential Reversal? Novavax Inc. (NVAX)

Novavax Inc. (NASDAQ: NVAX), a biotech company, reported last week that its COVID-19 vaccine has been approved in Japan. Similar permissions have already been reported by the firm in other places.

On April 19, Japanese regulatory authorities authorized Novavax’s Nuvaxovid vaccine for use in the main vaccination series as well as as a booster vaccine. Takeda Pharmaceutical Firm, a local company, gave assistance in the vaccine’s advertising.

Novavax formerly said that its vaccine had been authorized by the World Health Organization (WHO), as well as the European Union, Switzerland, India, Indonesia, South Korea, and other countries. The potential of an application in the United States is still being reviewed, but a favorable decision is expected soon.

Novavax plans to make $4 billion to $5 billion in income this year, thanks to its large list of authorized territories. Only $1 billion was received. Is the corporation going to be able to stick to the strategy this year? There is no one-size-fits-all solution. On one hand, there is

Novavax has finally started selling its COVID-19 vaccine, but it is doing so at a time when demand may not be as strong as it was a year and a half ago. Furthermore, even existing demands are not always met by Novavax. For example, vaccination delivery to large clients such as the Philippines was behind schedule in February.

The general scenario of the vaccine market, which already has significant rivals, does not inspire confidence. This will prohibit any manufacturer from boosting pricing, which might result in reduced margins in the long term, even for Novavax.

Many nations are now removing covid prohibitions, making it difficult to forecast immunization trends in the next months. Many previously vaccinated individuals refuse to get immunized because they believe the threat has passed.

Novavax Inc.’s (NVAX) stock declined -5.56% on Tuesday, closing at $47.42. The stock has dropped -64.96% in the previous six months, and -38.58% in the last three months.

Leave a Comment

Your email address will not be published.